Matthew Meyerson

Matthew Meyerson has been a leader in cancer genome characterization as a key contributor to The Cancer Genome Atlas, discovering major oncogenic drivers including ALK fusions in lung cancer and ROS1 rearrangements that have led to FDA-approved targeted therapies. His cancer dependency mapping efforts at the Broad Institute have systematically identified vulnerabilities across hundreds of cancer cell lines, creating a comprehensive resource for precision oncology. His integrative multi-omics analysis of lung and other cancers has exemplified the power of the omics revolution to identify clinically actionable cancer biology.